Abstract
Diuretics play an essential role in modern cardiovascular therapy, and are currently recommended for the treatment of congestive heart failure. Torasemide has been developed as a newer type of loop diuretic with a longer halflife, longer duration of action, and higher bioavailability compared to the most commonly used loop diuretic, furosemide. Torasemide also appears to have additional actions beyond the pure diuretic effect, such as anti-aldosterone effect and vasorelaxation effect. Studies have also investigated whether the superior pharmacokinetics and pharmacological activity of torasemide result in a favorable clinical outcome. Their results have indicated that, in comparison with furosemide, torasemide improves left ventricular function, reduces mortality as well as the frequency and duration of heart failurerelated hospitalization, and improves quality of life, exercise tolerance and NYHA functional class in patients with congestive heart failure. Thus, torasemide appears to be a promising loop diuretic that contributes to a better management of patients with heart failure. Definitive clinical trials in a double-blind fashion are warranted.
Keywords: Diuretics, furosemide, heart Failure, torasemide
Cardiovascular & Hematological Disorders-Drug Targets
Title: Torasemide for the Treatment of Heart Failure
Volume: 8 Issue: 2
Author(s): Hirotaka Ishido and Hideaki Senzaki
Affiliation:
Keywords: Diuretics, furosemide, heart Failure, torasemide
Abstract: Diuretics play an essential role in modern cardiovascular therapy, and are currently recommended for the treatment of congestive heart failure. Torasemide has been developed as a newer type of loop diuretic with a longer halflife, longer duration of action, and higher bioavailability compared to the most commonly used loop diuretic, furosemide. Torasemide also appears to have additional actions beyond the pure diuretic effect, such as anti-aldosterone effect and vasorelaxation effect. Studies have also investigated whether the superior pharmacokinetics and pharmacological activity of torasemide result in a favorable clinical outcome. Their results have indicated that, in comparison with furosemide, torasemide improves left ventricular function, reduces mortality as well as the frequency and duration of heart failurerelated hospitalization, and improves quality of life, exercise tolerance and NYHA functional class in patients with congestive heart failure. Thus, torasemide appears to be a promising loop diuretic that contributes to a better management of patients with heart failure. Definitive clinical trials in a double-blind fashion are warranted.
Export Options
About this article
Cite this article as:
Ishido Hirotaka and Senzaki Hideaki, Torasemide for the Treatment of Heart Failure, Cardiovascular & Hematological Disorders-Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/187152908784533685
DOI https://dx.doi.org/10.2174/187152908784533685 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological and Pharmacological Activities of Iridoids: Recent Developments
Mini-Reviews in Medicinal Chemistry Bioactive Fish Fatty Acids: Health Effects and Their Use as Functional Food Ingredients
Current Nutrition & Food Science Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Editorial from Guest Editor: Current Management of Sleep Apnea and Comorbidities
Current Respiratory Medicine Reviews <i>In silico</i> Approach for Exploring the Role of AT1R Polymorphism on its Function, Structure and Drug Interactions
Current Computer-Aided Drug Design Mechanisms Underlying Chemopreventive Effects of Flavonoids via Multiple Signaling Nodes within Nrf2-ARE and AhR-XRE Gene Regulatory Networks
Current Chemical Biology Pathophysiology of Myocardial Infarction and Acute Management Strategies
Cardiovascular & Hematological Agents in Medicinal Chemistry Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy The Renin-Angiotensin System: The Role of Inhibitors, Blockers, and Genetic Polymorphisms in the Treatment and Prevention of Heart Failure
Current Vascular Pharmacology Single Emulsion-Solvent Evaporation Technique and Modifications for the Preparation of Pharmaceutical Polymeric Nanoparticles
Recent Patents on Drug Delivery & Formulation Editorial [Hot Topic:Anabolic Androgenic Steroids (AAS) as Doping Agents: Chemical Structures,Metabolism, Cellular Responses, Physiological and Pathological Effects (Guest Editor: V. Fineschi)]
Mini-Reviews in Medicinal Chemistry Interaction of Wharton's Jelly Derived Fetal Mesenchymal Cells with Tumor Cells
Current Stem Cell Research & Therapy Nitric Oxide Pathway as New Drug Targets for Refractory Hypertension
Current Pharmaceutical Design Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets Current Treatment of the Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Sleep Apnea and Atrial Fibrillation; 2012 Update
Current Cardiology Reviews Taking a Systems Approach to the Identification of Novel Therapeutic Targets and Biomarkers
Current Pharmaceutical Biotechnology From Gene to Epigene-Based Therapies Targeting the Vascular Endothelium
Current Vascular Pharmacology NFAT Gene Family in Inflammation and Cancer
Current Molecular Medicine Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design